Neonatology

Sources of Neonatal Medicine

Bronchopulmonary Dysplasia: Then and Now

Philip A.G.S.

Author affiliations

Division of Neonatal and Developmental Medicine, Stanford University School of Medicine, Palo Alto, Calif., USA

Keywords: Bronchopulmonary dysplasiaChronic lung diseasePrematurityOxygenAssisted ventilation

Related Articles for ""
Neonatology 2012;102:1–8
https://doi.org/10.1159/000336030

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Sources of Neonatal Medicine

Received: December 22, 2011
Accepted: December 22, 2011
Published online: February 18, 2012
Issue release date: June 2012

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 0

ISSN: 1661-7800 (Print)
eISSN: 1661-7819 (Online)

For additional information: https://www.karger.com/NEO

Abstract

When bronchopulmonary dysplasia (BPD) was first described in 1967, the use of assisted ventilation in neonates was in its infancy. High concentrations of oxygen were implicated, and BPD was equated with ‘pulmonary oxygen toxicity’. The etiologic role of not only oxygen but also peak inspiratory pressures and the duration of exposure to both was emphasized in the 1970s, but BPD remained a dreaded complication of managing respiratory distress syndrome in the 1980s. It was only after exogenous surfactant became commercially available for endotracheal administration that ‘classical’ BPD began to disappear and was replaced by the ‘new’ BPD. ‘Classical’ BPD was seen in more mature preterm infants (>28 weeks’ gestational age) and in its severe form was characterized radiographically by micro- and macrocysts of the lung, lung hyperinflation and flattening of the diaphragms. In contrast, ‘new’ BPD is seen in less mature infants (<28 weeks’ gestational age), has comparatively mild radiographic abnormalities and has been defined as continued oxygen requirement at 36 weeks’ postmenstrual age. Pathologically, ‘classical’ BPD frequently revealed obstructive bronchiolitis and fibrosis of lung parenchyma, whereas ‘new’ BPD demonstrates minimal fibrosis but uniform arrest of development. Herein, factors which may contribute to the etiology of BPD are described, as well as possible preventative and therapeutic strategies.

© 2012 S. Karger AG, Basel



Related Articles:

References

  1. Northway WH Jr, Rosan RC, Porter DY: Pulmonary disease following respirator therapy of hyaline membrane disease: bronchopulmonary dysplasia. N Engl J Med 1967;276:357–368.
    External Resources
  2. Hawker JM, Reynolds EOR, Taghizadeh A: Pulmonary surface tension and pathological changes in infants dying after respirator treatment for severe hyaline membrane disease. Lancet 1967;ii:75–77.
    External Resources
  3. Kaplan HP, Robinson FR, Kapanci Y, Weibel ER: Pathogenesis and reversibility of the pulmonary lesions of oxygen toxicity in monkeys. 1. Clinical and light microscopic studies. Lab Invest 1969;20:94–100.
    External Resources
  4. Wilson MJ, Mikity VG: A new form of respiratory disease in premature infants. Am J Dis Child 1960;99:489–499.
    External Resources
  5. Philip AGS: Chronic lung disease of prematurity: a short history. Semin Fetal Neonatal Med 2009;14:333–338.
    External Resources
  6. Hodgman JE: Relationship between Wilson-Mikity syndrome and the new bronchopulmonary dysplasia. Pediatrics 2003;112:1414–1415.
    External Resources
  7. Philip AGS: Oxygen plus pressure plus time: the etiology of bronchopulmonary dysplasia. Pediatrics 1975;55:45–50.
  8. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T: Artificial surfactant therapy in hyaline membrane disease. Lancet 1980;i:55–59.
    External Resources
  9. Jobe AJ: The new BPD: an arrest of lung development. Pediatr Res 1999;46:641–643.
    External Resources
  10. Nelson NM: Chronology, morphology and physiology of pulmonary oxygen toxicity; in Lucey JF (ed): Problems of Neonatal Intensive Care Units. Report of the 59th Ross Conference on Pediatric Research. Columbus, Ross Laboratories, 1969, p 44.
  11. Pusey VA, MacPherson RI, Chernick V: Pulmonary fibroplasia following prolonged artificial ventilation of newborn infants. Can Med Assoc J 1969;100:451–457.
    External Resources
  12. Liggins GC, Howie RN: A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972;50:515–525.
    External Resources
  13. McCarthy MUS: Recommendations for antenatal corticosteroids. Lancet 1994;343:726.
    External Resources
  14. Jobe AH, Bancalari E: Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163:1723–1729.
    External Resources
  15. Walsh MC, Yao Q, Gettner PP, Hale E, Collins M, Hensman A, Everette R, Peters N, Miller N, Muran G, Auten K, Newman N, Rowan G, Grisby C, Arnell K, Miller L, Ball B, McDavid G; National Institute of Child Health and Human Development Neonatal Research Network: Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics 2004;114:1305–1311.
    External Resources
  16. Coalson JJ: Pathology of new bronchopulmonary dysplasia. Semin Neonatol 2003;8:73–81.
    External Resources
  17. Pfister RH, Soll RF: Pulmonary care and adjunctive therapies for prevention and amelioration of bronchopulmonary dysplasia. Neoreviews 2011;12:e635–e643.
    External Resources
  18. Spence KL, Zozobrado JC, Patterson BW, Hamvas A: Substrate utilization and kinetics of surfactant metabolism in evolving bronchopulmonary dysplasia. J Pediatr 2005;147:480–485.
    External Resources
  19. Guttentag S, Foster CD: Update in surfactant therapy. Neoreviews 2011;12:625–633.
    External Resources
  20. Saugstad OD: Oxygen radicals and pulmonary damage. Pediatr Pulmonol 1985;1:167–175.
    External Resources
  21. Speer CP, Halliday HL: Ola Didrik Saugstad – an oxygen radical. Neonatology 2008;94:188–189.
    External Resources
  22. Escobar J, Cernada M, Vento M: Oxygen and oxidative stress in the neonatal period. Neoreviews 2011;12:613–623.
    External Resources
  23. Brown ER, Stark A, Sosenko I, Lawson EE, Avery ME: Bronchopulmonary dysplasia: possible relationship to pulmonary edema. J Pediatr 1978;92:982–984.
    External Resources
  24. Watterberg KL, Carmichael DF, Gerdes JS, Werner S, Backstrom C, Murphy S: Secretory leukocyte protease inhibitor and lung inflammation in developing bronchopulmonary dysplasia. J Pediatr 1994;125:264–269.
    External Resources
  25. Watterberg KL, Demers LM, Scott SM, Murphy S: Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 1996;97:210–215.
    External Resources
  26. Speer CP: Inflammation and bronchopulmonary dysplasia. Semin Neonatol 2003;8:29–38.
    External Resources
  27. Bose CL, Dammann CE, Laughon MM: Bronchopulmonary dysplasia and inflammatory biomarkers in the premature neonate. Arch Dis Child Fetal Neonatal Ed 2008;93:F455–F461.
    External Resources
  28. Viscardi RM, Muhumuza CK, Rodriguez A, Fairchild KD, Sun CC, Gross GW, Campbell AB, Wilson PD, Hester L, Hasday JD: Inflammatory markers in intrauterine and fetal blood and cerebrospinal fluid compartments are associated with adverse pulmonary and neurological outcomes in preterm infants. Pediatr Res 2004;55:1009–1017.
    External Resources
  29. Thomas W, Speer CP: Chorioamnionitis: important risk factor or innocent bystander for neonatal outcome? Neonatology 2011;99:177–187.
    External Resources
  30. Katzenstein A, Davis C, Braude A: Pulmonary changes in neonatal sepsis due to group B beta-hemolytic streptococcus: relation to hyaline membrane disease. J Infect Dis 1976;133:430–435.
    External Resources
  31. Frank L, Sosenko IR: Undernutrition as a major contributing factor in the pathogenesis of bronchopulmonary dysplasia. Am Rev Respir Dis 1988;138:725–729.
    External Resources
  32. Wilson DC, McClure G, Halliday HL, Reid MM, Dodge JA: Nutrition and bronchopulmonary dysplasia. Arch Dis Child 1991;66:37–38.
    External Resources
  33. Bose CL, van Marter LJ, Laughon MM, O’Shea TM, Allred EN, Karna P, Ehrenkranz RA, Boggess K, Leviton A; Extremely Low Gestational Age Newborn Study Investigators: Fetal growth restriction and chronic lung disease among infants born before the 28th week of gestation. Pediatrics 2009;124:e450–e458.
    External Resources
  34. Clark DA, Pincus LG, Oliphant M, Hubbell C, Oates RP, Davey FR: HLA-A2 and chronic lung disease in neonates. J Am Med Assoc 1982;248:1868–1869.
    External Resources
  35. Bhandari V, Gruen JR: The genomics of bronchopulmonary dysplasia. Neoreviews 2007;8:e336–e344.
    External Resources
  36. Abman SH, Mourani PM, Sontag M: Bronchopulmonary dysplasia: a genetic disease. Pediatrics 2008;122:658–659.
    External Resources
  37. Merritt TA, Deming DD, Boynton BR: The ‘new’ bronchopulmonary dysplasia: challenges and commentary. Semin Fetal Neonatal Med 2009;14:345–357.
    External Resources
  38. Avery ME, Tooley WH, Keller JE, et al: Is chronic lung disease in low birth weight infants preventable? A survey of eight centers. Pediatrics 1987;79:26–30.
    External Resources
  39. Shenai JP, Kennedy KA, Chytil F, Stahlman MT: Clinical trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia. J Pediatr 1987;111:269–277.
    External Resources
  40. Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, Ehrenkranz RA, Stoll BJ, Lemons JA, Stevenson DK, Bauer CR, Korones SB, Fanaroff AA: Vitamin A supplementation for extremely low birth weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 1999;340:1962–1968.
    External Resources
  41. Doi T, Sugimoto K, Puri P: Prenatal retinoic acid up-regulates pulmonary gene expression of COUP-TFll, FOG2 and GATA4 in pulmonary hypoplasia. J Pediatr Surg 2009;44:1933–1937.
    External Resources
  42. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W; Caffeine for Apnea of Prematurity Trial Group: Caffeine therapy for apnea of prematurity. N Engl J Med 2006;354:2112–2121.
    External Resources
  43. Schmidt B, Roberts R, Miller D, Kirpalani H: Evidence-based neonatal drug therapy for prevention of bronchopulmonary dysplasia in very low birth-weight infants. Neonatology 2008;93:284–287.
    External Resources
  44. van Marter LJ, Leviton A, Kuban KCK: Maternal glucocorticoid therapy and reduced risk of bronchopulmonary dysplasia. Pediatrics 1990;86:331–336.
    External Resources
  45. Mammel MC, Green TP, Johnson DE, Thompson TR: Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet 1983;i:1356–1358.
    External Resources
  46. Avery GB, Fletcher AB, Kaplan M, Brudno DS: Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics 1985;75:106–111.
    External Resources
  47. Cummings JJ, D’Eugenio DB, Gross SJ: A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med 1989;320:1505–1510.
    External Resources
  48. Durand M, Sardesai S, McEvoy C: Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized controlled trial. Pediatrics 1995;95:584–590.
    External Resources
  49. Stark AR: Risks and benefits of post-natal corticosteroids. Neoreviews 2005;6:e99–e103.
    External Resources
  50. Doyle LW, Ehrenkranz RA, Halliday HL: Dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010;98:217–224.
    External Resources
  51. Doyle LW, Ehrenkranz RA, Halliday HL: Dexamethasone treatment after the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010;98:289–296.
    External Resources
  52. Egberts J, Brand R, Walti H, Bevilacqua G, Breart G, Gardini F: Mortality, severe respiratory distress syndrome and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant Curosurf. Pediatrics 1997;100:E4.
    External Resources
  53. Speer CP: Neonatal respiratory distress syndrome (RDS): an inflammatory disease? Neonatology 2011;99:316–319.
    External Resources
  54. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Carlo WA, Finer NN, Walsh MC, Rich W, Gantz MG, Laptook AR, Yoder BA, Faix RG, Das A, Poole WK, Schibler K, Newman NS, Ambalavanan N, Frantz ID 3rd, Piazza AJ, Sánchez PJ, Morris BH, Laroia N, Phelps DL, Poindexter BB, Cotten CM, Van Meurs KP, Duara S, Narendran V, Sood BG, O’Shea TM, Bell EF, Ehrenkranz RA, Watterberg KL, Higgins RD: Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med 2010;362:1959–1969.
    External Resources
  55. Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill JD, Walsh MC, Durand DJ, Mayock DE, Eichenwald EC, Null DR, Hudak ML, Puri AR, Golombek SG, Courtney SE, Stewart DL, Welty SE, Phibbs RH, Hibbs AM, Luan X, Wadlinger SR, Asselin JM, Coburn CE; NO CLD Study Group: Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 2006;355:343–353.
    External Resources
  56. Mercier JC, Hummler H, Durrmeyer X, Sanchez-Luna M, Carnielli V, Field D, Greenough A, Van Overmeire B, Jonsson B, Hallman M, Baldassarre J; EUNO Study Group: Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomized controlled trial. Lancet 2010;376:346–354.
    External Resources
  57. Abman SH: Pulmonary vascular disease and bronchopulmonary dysplasia: evaluation and treatment of pulmonary hypertension. Neoreviews 2011;12:e645–e650.
    External Resources
  58. Alphonse RS, Thébaud B: Growth factors, stem cells and bronchopulmonary dysplasia. Neonatology 2011;99:326–337.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Sources of Neonatal Medicine

Received: December 22, 2011
Accepted: December 22, 2011
Published online: February 18, 2012
Issue release date: June 2012

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 0

ISSN: 1661-7800 (Print)
eISSN: 1661-7819 (Online)

For additional information: https://www.karger.com/NEO

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2012, Vol.102, No. 1

June 2012

Article

Recommend This
TOP